Aggregate 13F filings for the Q2 2025 reporting period reveal that institutional investors significantly increased their collective holdings in AbbVie Inc (ABBV), adding 8.68 million shares for a total of 237.4 million shares, representing a 3.80% increase from the prior quarter. This overall accumulation, despite the inherent limitations of 13F data only reflecting long positions, suggests growing institutional conviction in ABBV, with Geode Capital Management, Bank of New York Mellon, and Massachusetts Financial Services Co. among the largest holders.
Analysis of 13F filings for the period ending June 30, 2025, reveals a net positive institutional sentiment towards AbbVie Inc. (ABBV). Across all 4,508 reporting funds, aggregate holdings increased by 8,681,659 shares, a 3.80% rise to a total of 237,395,195 shares. This broad-based accumulation suggests growing conviction among institutional investors. However, a smaller, more recent sample of 28 funds presented a conflicting picture, with a net decrease of 368,170 shares, heavily influenced by significant position reductions from firms like Citigroup and Nomura Asset Management. While the article correctly notes that 13F filings are an incomplete metric as they exclude short positions, the significant overall increase in long positions, anchored by major holders like Geode Capital Management and Bank of New York Mellon, indicates a prevailing bullish stance from the wider institutional community.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
